Skip to content
Tools

Peptide label guide

Peptide supplements vs injections: label and record checks

A document-first map for comparing product labels, facility records, FDA records, and certificates. It separates the question each record can answer.

TL;DR

Check route and intended use first, then open the matching label, approval, compounding, facility, and testing records. Each document answers a separate question.

Laboratory glassware arranged around an open work surface
Photo by Tara Winstead on Pexels.
Published: 2026-08-26Last reviewed: 2026-08-2613 min read

Key takeaways

  • FDA does not approve dietary supplements before marketing.[4] Its May 4, 2026 consumer guide describes approval as the rule for new human drugs and biological products, with rare exceptions, before marketing or interstate shipment.[1]
  • FDA says compounded drugs are not FDA-approved.[2] It applies different quality and oversight rules to the section 503A pharmacy-or-physician path and section 503B outsourcing facilities.[9]
  • When a Supplement Facts panel is required, it names dietary ingredients and states required amounts, with separate rules for proprietary blends.[3]
  • A 2024 review of oral bioactive peptide delivery identifies limited oral bioavailability as a substantial barrier.[6]
  • In a March 31, 2026 warning letter, FDA treated seller website claims as product labeling that showed intended human drug use despite research-use-only wording.[7]
  • FDA says a dietary supplement is swallowed and contains a dietary ingredient meant to supplement the diet.[4]

Skip to:

Route and intended use come before approval status

The document sequence for products sold with peptide language
CheckOpenWhat it can establishLimit
Check1. RouteOpenProduct form and directionsWhat it can establishWhether the label directs swallowing or injection. FDA says a dietary supplement is intended for ingestion.[4]LimitA swallowed format still must contain a qualifying dietary ingredient and meet the definition's other conditions.[4]
Check2. Ingredient directoryOpenFDA's ingredient directory and the linked agency action or communicationWhat it can establishWhether FDA links an action or communication that says an ingredient is excluded from the dietary supplement definition.[5]LimitThe directory is not comprehensive and may omit FDA actions, so no listing there does not establish qualification.[5]
Check3. Intended useOpenFull product labeling, including seller claimsWhat it can establishHow the seller presents the product.LimitResearch-use wording does not settle status.[7] FDA treated website claims as product labeling when assessing intended human-drug use.[7]
Check4. FDA approvalOpenCurrent FDA approval record and prescribing labelWhat it can establishThat FDA approved the drug or biological product for its intended use.[1]LimitThe record establishes approval only for the product and intended use it identifies.[1] Dietary supplements are not approved before marketing, although some new dietary ingredients trigger a premarket notification.[4] An NDC number, facility registration, or product listing is not FDA approval.[29][1]
Check5. New dietary ingredient recordOpenFDA's NDI process page, submitted-notification list, and the record linked from the list entryWhat it can establishWhether FDA's public list contains a notification by number, ingredient, notifier, submission date, and response date.[31] Open the linked record to read the notification and FDA response.[31]LimitThe filing and response record show what was submitted and how FDA answered; they do not establish supplement approval.[4] When notification is required, FDA says it must include the basis for expecting the supplement to be safe under the conditions stated in its labeling.[30] FDA's published Mitrasafe correspondence quotes the agency's 1997 rulemaking: acknowledging receipt does not establish safety or non-adulteration.[32]
Check6. Section 503A compounderOpenCheck the compounder's license and setting.[39] The statute covers a licensed pharmacist working in a pharmacy licensed by its state or in a federal facility.[39] It separately covers a licensed physician and is subject to the applicable prescription-order conditions.[39]What it can establishWhether the records fit patient-specific compounding or the statute's limited advance-compounding conditions.[39] Limited advance preparation requires a history of valid prescriptions for the same compounded product, generated only within an established relationship with either the patient or the future prescriber.[39]LimitLicensure alone does not establish every condition of section 503A.[10]
Check7. Section 503B facilityOpenFDA's registered-facility table and public product-report databaseWhat it can establishA facility registered as an outsourcing facility must compound drugs there only under section 503B.[40] Match the facility name and city and state in FDA's table, then check its registration, inspection, and action columns.[13] FDA says that table excludes State Board of Pharmacy actions and directs readers to the board for the facility's state.[13] Search the exact facility in FDA's public product-report database.[14]LimitRegistration confirms filing receipt.[11] It does not prove FDA approval, current good manufacturing practice compliance, or satisfaction of every 503B condition.[11] A no-hit cannot resolve production outside the last two years because the public database contains the last four reporting periods.[15]
Check8. Section 503A bulk-substance pathOpenApplicable monograph, approved-drug component record, and 503A Bulks ListWhat it can establishComply with the USP chapter on pharmacy compounding and with an applicable USP or NF monograph if one exists.[17] Without a monograph, check whether the substance is a component of an approved drug.[17] Only when neither branch applies does the 503A Bulks List branch apply.[17]LimitEvery bulk substance also needs a valid certificate of analysis from an FDA-registered manufacturer.[17]
Check9. Section 503A interim-category limitsOpenCurrent interim category, Category 2 safety table, and interim policyWhat it can establishFDA keeps Category 2 substances off the Category 1 interim path after finding significant safety risks.[17] Category 3 stays off that path when the supporting record is insufficient.[17] FDA says it does not intend to put bulk drug substances nominated on or after January 7, 2025 into those categories.[17]LimitFor older Category 1 substances, enforcement discretion is conditional and does not put a substance on the 503A Bulks List.[17] The interim policy still requires a valid certificate of analysis and registration for the original manufacturer and each later manufacturer.[19]
Check10. Section 503B bulk-substance pathOpen503B Bulks List, dated shortage records, and any applicable monographWhat it can establishThe bulk drug substance must appear on the 503B Bulks List, or the drug product compounded from it must appear on FDA's shortage list at compounding, distribution, and dispensing.[18] An applicable USP or NF monograph must also be followed.[18] Every bulk substance also needs a valid certificate of analysis from an FDA-registered manufacturer.[18]LimitThe shortage branch applies to the drug product compounded from the bulk substance, not necessarily to the bulk substance itself.[18]
Check11. Section 503B interim and shortage limitsOpenDated shortage records, current interim category, and the Category 2 safety tableWhat it can establishFor existing orders received while a drug was in shortage, FDA says it may act if an outsourcing facility keeps filling them more than 60 days after the drug leaves the shortage list.[21]LimitThe 503B interim page uses the same Category 2 and Category 3 exclusions as the 503A path: significant safety risks keep Category 2 out, and an insufficient supporting record keeps Category 3 out.[18] FDA also says it does not intend to put bulk drug substances nominated on or after January 7, 2025 into those categories.[18] For older Category 1 substances, the interim policy still requires a valid certificate of analysis and registration for the original manufacturer and each later manufacturer.[20]
Check12. Section 503A copy ruleOpenSection 503A, FDA's current shortage list, and FDA's final copy guidanceWhat it can establishUnder section 503A, a compounder may not regularly, or in inordinate amounts, make drugs that are essentially copies of a commercially available product.[39] FDA says a drug on its current shortage list is not treated as commercially available for this 503A test.[21] A change for an identified patient that the prescriber finds produces a significant difference falls outside that copy definition.[39]LimitEvery other section 503A condition still applies when a drug is on the shortage list.[21] FDA recommends keeping records of significant-difference notes, how often copies are made, and how many copy prescriptions were filled.[22]
Check13. Section 503B copy ruleOpenSection 503BWhat it can establishFor identical or nearly identical copies of an approved drug, the shortage-list exception applies only while that approved drug remains listed at compounding, distribution, and dispensing.[40] A separate bulk-component branch allows an exception when a prescriber finds that a change produces a clinical difference for one patient.[40]LimitThe shortage and clinical-difference exceptions belong to separate statutory branches.[40]
Check14. Withdrawn and difficult-to-compound productsOpenSections 503A and 503B, the withdrawn-or-removed list, and FDA's current policy tableWhat it can establishBoth paths exclude drugs on FDA's withdrawn-or-removed list.[10]LimitSection 503A bars a product that FDA identifies by final regulation as presenting demonstrable difficulties for compounding.[39] Under section 503B, a listed difficult-to-compound product may be made only under every applicable condition FDA identifies for it.[40] Every other section 503B condition still applies.[40] FDA's current policy table labels its March 19, 2024 demonstrable-difficulties action as a proposed rule.[25]
Check15. Section 503A interstate distributionOpenSection 503A, FDA's current compounding-MOU page, and FDA's enforcement noticeWhat it can establishSection 503A links interstate distribution to a state memorandum of understanding, or to a statutory 5 percent limit in a state without one.[39] FDA's current page, last updated January 23, 2023, says its three listed compounding MOUs are suspended.[23] FDA's 2022 notice extends the period before enforcement of the 5 percent limit until a final rule takes effect and an updated standard MOU is published.[24]LimitThe enforcement posture can change. Reopen both FDA records before relying on it.
Check16. Product, compounder, and transfer matchOpenProduct label, the named 503B facility's FDA product report, and seller record, when applicableWhat it can establishWhat the facility reported making during the prior six-month period, including active ingredient, strength, dosage form, and route.[16]LimitOutsourcing facilities submit these reports themselves.[16] Section 503B generally bars sale or transfer by an entity other than the outsourcing facility that compounded the drug, with exceptions for administration in a healthcare setting and prescription dispensing.[40]
Check17. Label declarationOpenSupplement Facts for a supplement or the compounded-product label for a 503B drugWhat it can establishDeclared dietary ingredient names, required amount information, and serving information, subject to proprietary blend rules.[3] A 503B label must state "This is a compounded drug" or a Secretary-specified reasonable comparable alternative, and include the outsourcing facility name, address, phone number, lot or batch number, and other specified information.[40]LimitDietary supplements and compounded drugs do not receive premarket FDA approval review.[4][2] Approval status for a drug or biological product stays with FDA's approval record for the product and intended use it identifies.[1] Section 503A has no parallel explicit federal labeling condition, so a label alone cannot establish that path.[10] Component test results belong in the matched certificate or testing record.[8]
Check18. Certificate of analysisOpenThe certificate of analysis matched to the material it identifiesWhat it can establishFor a supplier component certificate used under supplement current good manufacturing practice, test methods, limits, and actual results.[8]LimitA dietary ingredient still requires an identity test or examination unless FDA grants a petitioned alternative.[8] Supplier qualification happens before reliance on the certificate, and the supplier's certificate is then periodically reconfirmed.[8]

FDA's supplement definition also excludes certain approved drugs and licensed biologics.[4] An ingredient studied under an effective investigational new drug application can be excluded after substantial clinical investigations begin and become public.[4] Earlier marketing as food or a supplement is one exception.[4]

FDA says section 503B outsourcing facilities are primarily federally overseen and subject to current good manufacturing practice requirements.[9] Drug products compounded in accordance with every section 503A condition are exempt from those requirements.[10] A 503B facility may send prescription drugs to healthcare facilities without prescriptions for identified patients, but it cannot dispense a prescription drug directly to a patient without a prescription.[12]

Oral evidence does not establish injectable performance

The 2024 review addresses oral delivery and identifies limited oral bioavailability as a substantial barrier.[6] Its scope is oral delivery, not injectable research vials.[6]

FDA's consumer guide describes the approval standard for drugs and biological products.[1]

A certificate cannot replace approval or compounder records

FDA's approval record carries approval status.[1] For 503A, check the compounder's license, setting, and applicable prescription-order conditions.[39] For 503B, check the exact facility's registration, inspection record, and public product report.[13][14]

The Peptide COA vs Supplement Facts guide shows how to keep a declared amount separate from a batch test result.

Research-use labeling and named-substance context stay separate

When a product carries research-use wording, open the research-use-only peptide vial guide for the separate product-labeling checks. After the regulatory branch is clear, the pepSmart peptide library can supply named-substance context and aliases. It does not replace the current FDA record, a batch-linked report, or the government and journal sources listed with this article.

Related peptide label guides

Peptide status guide

What "research use only" means in peptide product labeling

Use the document map to compare seller wording with approval, intended-use, supplier-COA, and human-evidence records.

Peptide document guide

Peptide COA vs Supplement Facts: what each can prove

Use the field-by-field guide to compare a Supplement Facts panel with a supplier COA without treating either document as proof of the other.

Peptide evidence guide

Collagen peptides vs BPC-157: two evidence records

Use the side-by-side guide to keep collagen, BPC-157, formulation, route, population, and regulatory status in separate evidence lanes.

Peptide math guide

Peptide vial concentration vs dose: keep them apart

Use the symbolic worksheet to keep label fields and unit-conversion steps separate without choosing an amount to administer.

Sources behind this guide

  1. Is It Really 'FDA Approved'?. U.S. Food and Drug Administration. Source date: 2026-05-04.
  2. Understanding the Risks of Compounded Drugs. U.S. Food and Drug Administration. Source date: 2026-06-22.
  3. Dietary Supplement Labeling Guide: Chapter IV. Nutrition Labeling. U.S. Food and Drug Administration. Content current as of: 2005-04-01.
  4. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration. Source date: 2024-02-21.
  5. Information on Select Dietary Supplement Ingredients and Other Substances. U.S. Food and Drug Administration. Source date: 2026-05-01.
  6. Obstacles, research progress, and prospects of oral delivery of bioactive peptides: a comprehensive review. Frontiers Media SA. Source date: 2024-11-14.
  7. Gram Peptides MARCS-CMS 721806 - March 31, 2026. U.S. Food and Drug Administration. Source date: 2026-03-31.
  8. Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. U.S. Food and Drug Administration. Content current as of: 2018-09-20.
  9. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. Source date: 2025-09-16.
  10. FD&C Act Provisions that Apply to Human Drug Compounding. U.S. Food and Drug Administration. Source date: 2021-08-13.
  11. Questions and Answers: Outsourcing Facility Registration. U.S. Food and Drug Administration. Source date: 2019-07-02.
  12. Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. Source date: 2015-08.
  13. Registered Outsourcing Facilities. U.S. Food and Drug Administration. Accessed: 2026-04-13.
  14. Outsourcing Facility Product Report. U.S. Food and Drug Administration. Accessed: 2026-07-31.
  15. Information for Outsourcing Facilities. U.S. Food and Drug Administration. Source date: 2022-03-29.
  16. Human Drug Compounding Registration And Product Reporting Procedures. U.S. Food and Drug Administration. Source date: 2024-10-02.
  17. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Source date: 2026-05-14.
  18. Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act. U.S. Food and Drug Administration. Source date: 2025-01-07.
  19. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. Source date: 2025-01-07.
  20. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. Source date: 2025-01-07.
  21. Compounding when Drugs are on FDA's Drug Shortages List. U.S. Food and Drug Administration. Source date: 2025-08-08.
  22. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. U.S. Food and Drug Administration. Source date: 2018-01.
  23. Compounding MOUs. U.S. Food and Drug Administration. Content current as of: 2023-01-23.
  24. Extension of the Period Before the Food and Drug Administration Intends To Begin Enforcing the Statutory 5 Percent Limit on Out-of-State Distribution of Compounded Human Drug Products. U.S. Food and Drug Administration. Source date: 2022-10-21.
  25. Human Drug Compounding Policies and Rules. U.S. Food and Drug Administration. Source date: 2026-05-01.
  26. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. Source date: 2026-06-15.
  27. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. Source date: 2026-04-01.
  28. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. Document date: 2026-05-14.
  29. National Drug Code Directory. U.S. Food and Drug Administration. Source date: 2026-03-04.
  30. New Dietary Ingredient (NDI) Notification Process. U.S. Food and Drug Administration. Source date: 2025-06-11.
  31. Submitted 75-Day Premarket Notifications for New Dietary Ingredients. U.S. Food and Drug Administration. Source date: 2026-07-10.
  32. FDA correspondence regarding the Mitrasafe new dietary ingredient notification. U.S. Food and Drug Administration. Source date: 2018-02-26.
  33. 21 CFR 216.23 -- Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. Electronic Code of Federal Regulations. Source date: 2026-07-29.
  34. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. Source date: 2026-04-22.
  35. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). U.S. Food and Drug Administration. Document date: 2026-05-11.
  36. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Source date: 2026-07-23.
  37. July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC), BPC-157 free base vote at 4:40. U.S. Food and Drug Administration. Source date: 2026-07-23.
  38. July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC), BPC-157 acetate vote at 4:51. U.S. Food and Drug Administration. Source date: 2026-07-23.
  39. 21 USC 353a: Pharmacy compounding. Office of the Law Revision Counsel, U.S. House of Representatives. Law current through: 2026-04-13.
  40. 21 USC 353b: Outsourcing facilities. Office of the Law Revision Counsel, U.S. House of Representatives. Law current through: 2026-07-30.

A 503B check needs recent inspection context

FDA registration confirms that the agency received a facility's required information.[11] A stronger 503B check pairs current registration with a recent satisfactory FDA inspection.[11] FDA calls an inspection a snapshot in time, and registration alone does not establish approval, compliance with current good manufacturing practice, or that every 503B condition is met.[11]

NutriScore has not commissioned independent clinical review of this article.

Read the editorial process and contributor disclosure and the scoring methodology.

Corrections: support@nutriscore.fit.

Sources: 40 entries, primary canon plus reputable secondary sources with inline acknowledgment, last reviewed 2026-08-26.

For research and educational purposes only. Not medical advice.